J F Gallo1, J M W Pinhata1, V Simonsen1, V M N Galesi2, L Ferrazoli1, R S Oliveira3. 1. Núcleo de Tuberculose e Micobacterioses, Centro de Bacteriologia, Instituto Adolfo Lutz, São Paulo, Brazil. 2. Divisão de Controle da Tuberculose, Centro de Vigilância Epidemiológica 'Prof. Alexandre Vranjac', São Paulo, Brazil. 3. Núcleo de Tuberculose e Micobacterioses, Centro de Bacteriologia, Instituto Adolfo Lutz, São Paulo, Brazil. Electronic address: rosangela.oliveira@ial.sp.gov.br.
Abstract
OBJECTIVES: To describe the prevalence, associated factors, treatment outcomes and transmission of extensively drug-resistant (XDR) tuberculosis (TB) in the state of São Paulo, Brazil, for 2011 to 2013. METHODS: Drug susceptibility testing to first- and second-line drugs was performed by BACTEC MGIT 960 and molecular typing, by IS6110 restriction fragment length polymorphism. Clinical, epidemiologic and demographic data were obtained from surveillance information systems for TB. Patients were divided into three groups: multidrug resistant (MDR) TB (resistance to at least isoniazid and rifampicin), pre-XDR-TB (MDR-TB resistant to a fluoroquinolone or to at least one of the second-line injectable drugs) and XDR-TB (MDR-TB resistant to a fluoroquinolone and to at least one of the second-line injectables). RESULTS: Among the 313 MDR-TB patients identified, the prevalence of XDR-TB and pre-XDR-TB was 10.2% (n = 32) and 19.2% (n = 60), respectively. Compared to MDR-TB patients, XDR-TB patients were more likely to be female (odds ratio (OR) = 2.74, 95% confidence interval (CI), 1.29-5.83), have a history of TB (OR = 5.16; 95% CI, 1.52-17.51) and present higher death rates (OR= 3.74; 95% CI 1.70-8.25). XDR-TB transmission was observed in households, between neighbours and between a patient and a healthcare worker in a hospital. CONCLUSIONS: The prevalence of XDR-TB in the state of São Paulo is close to that estimated globally. Most of the XDR-TB patients were treated previously for TB and presented the lowest successful outcome rates. Because transmission of XDR-TB occurred, it is important that timely diagnosis of drug resistance is performed.
OBJECTIVES: To describe the prevalence, associated factors, treatment outcomes and transmission of extensively drug-resistant (XDR) tuberculosis (TB) in the state of São Paulo, Brazil, for 2011 to 2013. METHODS: Drug susceptibility testing to first- and second-line drugs was performed by BACTEC MGIT 960 and molecular typing, by IS6110 restriction fragment length polymorphism. Clinical, epidemiologic and demographic data were obtained from surveillance information systems for TB. Patients were divided into three groups: multidrug resistant (MDR) TB (resistance to at least isoniazid and rifampicin), pre-XDR-TB (MDR-TB resistant to a fluoroquinolone or to at least one of the second-line injectable drugs) and XDR-TB (MDR-TB resistant to a fluoroquinolone and to at least one of the second-line injectables). RESULTS: Among the 313 MDR-TB patients identified, the prevalence of XDR-TB and pre-XDR-TB was 10.2% (n = 32) and 19.2% (n = 60), respectively. Compared to MDR-TB patients, XDR-TBpatients were more likely to be female (odds ratio (OR) = 2.74, 95% confidence interval (CI), 1.29-5.83), have a history of TB (OR = 5.16; 95% CI, 1.52-17.51) and present higher death rates (OR= 3.74; 95% CI 1.70-8.25). XDR-TB transmission was observed in households, between neighbours and between a patient and a healthcare worker in a hospital. CONCLUSIONS: The prevalence of XDR-TB in the state of São Paulo is close to that estimated globally. Most of the XDR-TBpatients were treated previously for TB and presented the lowest successful outcome rates. Because transmission of XDR-TB occurred, it is important that timely diagnosis of drug resistance is performed.
Authors: Emilyn Costa Conceição; Richard Steiner Salvato; Karen Machado Gomes; Arthur Emil Dos Santos Guimarães; Marília Lima da Conceição; Ricardo José de Paula Souza E Guimarães; Abhinav Sharma; Ismari Perini Furlaneto; Regina Bones Barcellos; Valdes Roberto Bollela; Lívia Maria Pala Anselmo; Maria Carolina Sisco; Cristina Viana Niero; Lucilaine Ferrazoli; Guislaine Refrégier; Maria Cristina da Silva Lourenço; Harrison Magdinier Gomes; Artemir Coelho de Brito; Marcos Catanho; Rafael Silva Duarte; Philip Noel Suffys; Karla Valéria Batista Lima Journal: Mem Inst Oswaldo Cruz Date: 2021-03-15 Impact factor: 2.743
Authors: Muhammad Abubakar; Nafees Ahmad; Abdul Ghafoor; Abdullah Latif; Izaz Ahmad; Muhammad Atif; Fahad Saleem; Shereen Khan; Amjad Khan; Amer Hayat Khan Journal: Front Pharmacol Date: 2021-03-31 Impact factor: 5.810
Authors: Selien Oostvogels; Serej D Ley; Tim H Heupink; Anzaan Dippenaar; Elizabeth M Streicher; Elise De Vos; Conor J Meehan; Keertan Dheda; Rob Warren; Annelies Van Rie Journal: Microb Genom Date: 2022-04
Authors: Otavio T Ranzani; Laura C Rodrigues; Sidney Bombarda; Cátia M Minto; Eliseu A Waldman; Carlos R R Carvalho Journal: Lancet Infect Dis Date: 2019-10-31 Impact factor: 71.421
Authors: Lauane G Araújo; Márcia T Garcia; Tânia R Zaccariotto; Maria Luiza Moretti; Carlos E Levy; Mariângela R Resende Journal: Braz J Infect Dis Date: 2021-02-13 Impact factor: 3.257